Home » Newsletters » BioWorld Science

BioWorld Science

July 19, 2005

View Archived Issues

Immune modulation therapy with Celacade benefits heart failure patients

Oral pimecrolimus reported effective in moderate to severe atopic dermatitis

Patupilone activity, safety gauged in phase I/II trial in non-small cell lung cancer

OGX-011 reported to be well tolerated when added to NSCLC chemotherapy

Malignant pleural mesothelioma patients achieve disease control with vinflunine

Caspase inhibitor prevents plaque progression in atherosclerotic mice

Novel adenosine A3 receptor antagonists reported

NO moiety in statins improves their therapeutic potential

Priority review for Exjade in Canada

SPA agreement for phase III study of renzapride for c-IBS

7TM Pharma begins phase I/II trials for TM-30338 for obesity

Astex Technology changes name to Astex Therapeutics

Albany Molecular Research partners with NINDS in spinal muscular atrophy

Tracleer study shows benefit in Eisenmenger's syndrome

Phase IIIb/IV ASSENT 4 PCI study of tenecteplase stopped early

MVA smallpox vaccine MVA-3000 begins phase II trial

Pagoclone studied in phase II trial for persistent developmental stuttering

Triglide launched in U.S.

VNS Therapy System receives FDA approval for treatment-resistant depression

Thelin NDA receives March 2006 action date

MATCHED study of MC-4232 completes treatment period

Novartis to acquire Bristol-Myers Squibb's OTC portfolio

Prous Science announces publication of a comprehensive review on Behcet's disease

NMP22 BladderChek Test approved in Japan

Recent patents cover therapeutic agents for cognitive impairment and neurodegeneration

Novel antithrombotic agents reported in recent patent literature

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...